Cincinnati, OHNCT05501756Now EnrollingIRB Ready

Allogeneic Hematopoietic Cell Transplantation Clinical Trial in Cincinnati, OH

Access cutting-edge allogeneic hematopoietic cell transplantation treatment through this clinical trial at a research site in Cincinnati. Study-provided care at no cost to qualified participants.

Sponsored by Children's Hospital Medical Center, Cincinnati

Quick Self-Assessment

See if you qualify for this Cincinnati location

Preparing your pre-screening questions…

Expert Care in Cincinnati

Access allogeneic hematopoietic cell transplantation specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related allogeneic hematopoietic cell transplantation treatment provided free

Apply for This Cincinnati Location

Check if you qualify for this allogeneic hematopoietic cell transplantation clinical trial in Cincinnati, OH

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Cincinnati

    Convenient for OH residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Cincinnati site if eligible
  4. 4Begin participation

About This Allogeneic Hematopoietic Cell Transplantation Study in Cincinnati

Alemtuzumab is an antibody that reduces the strength of the immune system that is given in preparation for allogeneic hematopoietic cell transplant (HCT). In this research study the investigators want to find out if they can adjust the dose of alemtuzumab used as part of allogeneic HCT to target the level of Day 0 (the planned day of graft infusion) to an optimal therapeutic window of 0.15-0.9 ug/mL.

Sponsor: Children's Hospital Medical Center, Cincinnati

Who Can Participate

Inclusion Criteria

Patients who are undergoing allogeneic HCT at CCHMC with an alemtuzumab-containing preparative regimen for treatment of a non-malignant disease are eligible.
For the first 7 patients, patients must have a 10/10 HLA matched related or unrelated stem cell donor, or be receiving a CD34+ selected stem cell product. After the first 7 patients, any donor match may be allowed after data review by the BMT clinicians and the PI.

Exclusion Criteria

Patients with a history of anaphylaxis to alemtuzumab.
Patients who have previously received alemtuzumab and have not cleared alemtuzumab prior to the start of the preparative regimen.
Life expectancy less than 4 weeks.
Patients receiving dialysis or plasmapheresis at the time of the start of the conditioning regimen.
Failure to sign informed consent and/or assent, or inability to undergo informed consent process.
It is not medically advisable to obtain the specimens necessary for this study.
Not able to tolerate subcutaneous dosing (patients with severe skin conditions).
Patients with cancer.
Patients whose clinical condition suggest there may be inability to successfully perform the PK modeling such as, but not limited to, active flaring of hemophagocytic lymphohistiocytosis in which excessive lymphoproliferation may significantly alter the target-mediated clearance of alemtuzumab and prevent observation of non-target mediated clearance which is needed for robust modeling.
Patients whose pre-alemtuzumab level reveals an interfering substance which prevents accurate measurement of alemtuzumab.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Cincinnati?

Yes, this clinical trial (NCT05501756) has an active research site in Cincinnati, OH that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Allogeneic Hematopoietic Cell Transplantation Treatment Options in Cincinnati, OH

If you're searching for allogeneic hematopoietic cell transplantation treatment options in Cincinnati, OH, this clinical trial (NCT05501756) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Cincinnati research site is actively enrolling participants for this clinical trial. You'll receive care from experienced allogeneic hematopoietic cell transplantation specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all allogeneic hematopoietic cell transplantation clinical trials near you to find additional studies recruiting in your area.

More Leukemia Trials in Cincinnati, OH

See all leukemia clinical trials recruiting in Cincinnati — not just this study.

Browse Leukemia Trials in Cincinnati →

Browse More Trials by Condition

Leukemia TrialsEssential Tremor TrialsRheumatoid Arthritis TrialsInterstitial Cystitis TrialsOrgan Transplant TrialsOsteogenesis Imperfecta TrialsAll Conditions →

Ready to Join in Cincinnati?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Cincinnati, OH